Modulation of Inflammatory Response and Induction of Bone Formation Based on Combinatorial Effects of Resveratrol

**Katye Rutledge, Qingguo Cheng and Ehsan Jabbarzadeh**

1Department of Chemical Engineering, University of South Carolina, Columbia, SC, 29208, USA
2Biomedical Engineering Program, University of South Carolina, Columbia, SC, 29208, USA
3Department of Orthopaedic Surgery, University of South Carolina School of Medicine, Columbia, SC, 29209, USA

**Abstract**

The success of bone tissue engineering strategies critically depends on the rapid formation of a mature vascular network in the scaffolds after implantation. Conventional methods to accelerate the infiltration of host vasculature into the scaffolds need to consider the role of host response in regulation of bone tissue ingrowth and extent of vascularization. The long-term goal of this study was to harness the potential of inflammatory response to enhance angiogenesis and bone formation in three-dimensional (3D) scaffolds. Towards this goal, we explored the use of resveratrol, a natural compound commonly used in complementary medicine, to enable the concurrently (i) mediate M1 to M2 macrophage plasticity, (ii) impart natural release of angiogenic factors by macrophages and (iii) enhance osteogenic differentiation of human mesenchymal stem cells (hMSCs). We mapped the time-dependent response of macrophage gene expression as well as hMSC osteogenic differentiation to varying doses of resveratrol. The utility of this approach was evaluated in 3D poly (lactide-co-glycolide) (PLGA) sintered microsphere scaffolds for bone tissue engineering applications. Our results altogether delineate the potential to synergistically accelerate angiogenic factor release and upregulate osteogenic signaling pathways by “dialing” the appropriate degree of resveratrol release.

**Keywords:** Resveratrol; Mesenchymal stem cells; Macrophage polarization; Inflammatory microenvironment; Osseointegration

**Introduction**

Tissue engineering offers a revolutionary approach to restore critical-size defects resulting from trauma, infection, tumor resection or other musculoskeletal diseases [1]. This is traditionally accomplished by utilizing a combination of biomaterials, cells, and signaling factors. Biomaterials provide a three-dimensional (3D) substrate with specific engineered characteristics for cells to attach and proliferate. Growth factors supply essential signaling cues for cells to migrate and differentiate into the desired tissue type. Cells seeded on 3D biomaterials contribute to the healing process through signaling events that guide newly formed tissue integration with the host tissue.

The success of tissue engineering strategies is contingent on the ability of blood vessels to form within the scaffolds and supply nutrients to the transplanted cells [2]. This process is controlled through a cascade of events that are mediated by host inflammatory response. Inflammation is the process by which the body protects itself from intruders, and if left uncontrolled, potentially interferes with the integration of implanted biomaterials. The complicated interplay of cells and cytokines at the interface of an implanted biomaterial must be deconstructed in order to properly design an approach to harness inflammation and promote wound healing.

The host inflammatory response is commonly initiated through the release of serum proteins from the vasculature binding to the implanted biomaterial and forming a provisional matrix composed of fibrin, platelet granule components such as thrombospondin, transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), platelet factor 4 (PF4), and platelet-derived endothelial cell growth factor (ECGF) [3]. This process is followed by monocytes exiting the capillaries, migrating to the surface of biomaterials, and differentiating into M1 macrophages. The secretion of cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and monocyte chemotactic protein 1 (MCP-1) drives the acute inflammation response [4,5]. The next event in the host response to an implanted biomaterial is chronic inflammation, which is defined by the presence of macrophages, monocytes, lymphocytes, blood vessel proliferation, and connective tissue formation [6-9]. Foreign body giant cells and macrophages exist at tissue-implant interface for the duration of the biomaterial’s lifetime [10-14]. A fibrous capsule forms as a result, separating the biomaterial from the host tissue [3]. Several strategies have been designed to modulate the host inflammation in response to biomaterials [15-23]. In one approach, a hydrophilic boundary between implant and host tissue was created to enhance the biocompatibility of implants. In another approach, anti-inflammatory biomolecules were utilized to inhibit the secretion of mediators such as leukotrienes and prostaglandins, and delay fibroblast capsule formation [24]. A major drawback of these methods is the numerous undesired systemic side effects [25]. For example, anti-inflammatory corticosteroid based drugs inhibit new blood vessel formation necessary for nutrient exchange in the implanted tissue [26,27]. Another commonly used method is the induction of angiogenesis based on the use of growth factors [28-30]. Despite its success, this method can overexpose tissues to growth factors leading to arthritis and tumor formation [31-33].

Efforts to identify compounds with anti-inflammation properties have led to discovery of resveratrol, a polyphenol found in the skin of grapes [34,35]. Strikingly, this molecule has been shown to exhibit therapeutic effects in a number of diseases including cancer.
cardiovascular failure, viral infections, neurodegeneration, and ischemic injuries [36-46]. The exact mechanisms by which resveratrol impacts inflammation is under intense investigation. Suppression of transcription factor nuclear factor kappa B (NF-κB), TNF-α and interleukin-1 (IL-1), prostaglandin E2 (PGE2), and nitric oxide (NO) synthesis have been demonstrated to be potential means by which resveratrol attenuates inflammation [47-49]. Further studies are warranted to explore the signaling cascades governing the anti-inflammatory potential of resveratrol in the context of wound healing and implant integration.

In addition to its anti-inflammatory characteristic, resveratrol has been found to possess pro-osteogenic properties [50]. Augmentation of Wnt signaling pathway, activation of sirtuin 1 (SIRT-1), and acetylation of runt-related transcription factor 2 (RUNX2) have been shown to be the underlying mechanism behind the induction of osteogenesis in stem cells by resveratrol [51-54]. Additionally, reports of the bone inductive effects of resveratrol through the activation of estrogen receptor have highlighted this natural compound as a viable candidate factor for bone tissue engineering applications.

The long term objective of this study is to delineate the potential of resveratrol to accelerate the formation of bone and vasculature in tissue engineered scaffolds. The major hypothesis underlying our effort is that resveratrol can be used to simultaneously (1) induce the osteogenic differentiation of hMSCs seeded onto 3D porous scaffolds, and (2) regulate the intricate balance of M1 – M2 macrophage phenotype switch. We tested these hypotheses by assessing the time-dependent effect of varying resveratrol doses on macrophage gene expression as well as hMSCs osteogenic differentiation in 2D and 3D culture systems.

Materials and Methods

Human monocyte cell culture

Human THP-1 monocytes (Sigma) were cultured in basal medium consisting of RPMI 1640 (Sigma), 2 mM L-Glutamine (Gibco), 10% FBS (Atlas), and 1% penicillin/streptomycin (Invitrogen). Medium was changed every other day, and cells were kept at a density of 3-8 x 10^6 cells/mL. THP-1 monocytes were seeded in each well of a 24 well plate at a number of 500,000 cells per well. Depending on the experimental conditions, cells were kept at an undifferentiated state, were differentiated to M0 macrophages, or were differentiated to M1 macrophages.

Differentiation of monocytes to macrophages

THP-1 monocytes were differentiated to M0 macrophages by adding 200 nM phorbol 12-myristate 13-acetate (PMA) to the basal medium for 24 hours after which cells adhered to the tissue culture plate. To differentiate M0 macrophages to M1 macrophages, basal medium supplemented with 1 μg/mL lipopolysaccharide (LPS) (Sigma) and 20 ng/mL recombinant interferon gamma (IFNγ) (Peprotech) was added to the wells for 24 hours. Differentiation of M0 macrophages to M2 macrophages was accomplished by adding 20 ng/mL recombinant interleukin 4 (IL-4) (Peprotech) as well as 20 ng/mL recombinant interleukin-13 (IL-13) (Peprotech) to the basal medium, and then culturing M0 macrophages in the differentiation medium for 18 hours.

Effect of resveratrol on M1 macrophages

Resveratrol was added to basal THP-1 monocytes culture medium at the concentrations of 1 μM, 10 μM, and 25 μM, and gene expression of cytokines VEGF, TNF-α, IL-6, macrophage mannose receptor 1 (MRC-1), and interleukin 10 (IL-10) were analyzed using qRT-PCR after resveratrol exposure durations of 2 and 5 days.

The total RNA was extracted and purified from the samples using the GeneJET RNA Purification Kit (Thermo Scientific). Briefly, RNA (0.5 μg) was prepared as a template for single-strand cDNA synthesis using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). First, genomic DNA was removed from the RNA sample by applying a mixture of the supplied reaction buffer with MgCl2, DNAse I, and nuclease-free water to a total volume of 10 μL. The samples were then incubated at 37°C for 30 minutes, after which 1 μL 50 mM EDTA was added.

The samples were placed in a 65°C water bath for 10 minutes. The template RNA was mixed with 1 μL oligo (dT) 18 primer and nuclease-free water to a volume of 12 μL, followed by the addition of 4 μL of 5X Reaction Buffer, 1 μL Ribolock RNase Inhibitor, 2 μL 10 mM dNTP Mix, and 1 μL RevertAid M-MuLV Reverse Transcriptase. This mixture was incubated at 42°C for 1 hour in a Bio-Rad CFX96 thermocycler instrument. To detect gene expression, the SensiFAST SYBR No-ROX Kit (Bioline) was used for qPCR. Briefly, 100 ng of cDNA was mixed with 10 μL 2X SensiFAST SYBR No-ROX Mix, 10 μM forward primer, 10 μM reverse primer. (Table 1 shows primer sequences, Integrated DNA Technologies) and nuclease-free water to 20 μL. A 3-step cycling was used on a Bio-Rad CFX96 instrument: 1 cycle of 95°C for 2 minutes to activate the polymerase, followed by 40 cycles of 95°C for 5 s to denature, 65°C for 10 s for annealing, and 10 s at 72°C for extension. Gene expression of VEGF, TNF-α, IL-6 MRC-1, and IL-10 were normalized to GAPDH and presented as relative values.

Human mesenchymal stem cell culture

Human bone marrow-derived mesenchymal stem cells were obtained from Lonza (Walkersville, MD). Human mesenchymal stem cells (hMSCs) were cultured in a basal medium consisting of DMEM/F12 (Gibco), 10% FBS (Atlas), and 1% penicillin/streptomycin (Invitrogen). Medium was changed every 5 days and cells were passaged once 80% confluency was reached.

Effect of resveratrol on hMSC proliferation and osteogenic differentiation

To study the impact of resveratrol on osteogenic differentiation, hMSCs were seeded in a 24 well plate (50,000 cells/well) for 24 h...
after which the culture medium was changed. Four conditions were considered in this study: basal medium (negative control), basal medium supplemented with 12.5 μM resveratrol (Sigma), osteogenic medium, or osteogenic medium supplemented with 12.5 μM resveratrol. ADSCs cultured with resveratrol exhibited the highest levels of osteocalcin and osteoprotegerin at a concentration of 12.5 μM [55]. Osteogenic medium consisted of DMEM F/12 (444 mL) (Invitrogen), fetal bovine serum (50 mL), β-glycerophosphate (10 mM), ascorbic acid (50 μg/mL) (Sigma), dexamethasone (1 μM) (Sigma), and penicillin/streptomycin (5 mL). Growth media was exchanged 3 times per week for all groups. Samples were characterized by MTS proliferation assay, osteocalcin immunofluorescence staining, Alizarin Red S staining, calcium quantification, alkaline phosphatase (ALP) staining, and ALP quantification.

Cell proliferation was monitored using [3-(4,5-dimethylthiazol-2-yl)]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) colorimetric assay. Fresh media was added to each well at a 100 μL volume, and incubated for 4 hours with 20 μL of MTS solution. The resulting solution was diluted 1:5 and the absorbance was read at 492 nm using a Biotek Synergy 2 plate reader.

Osteocalcin was qualitatively assessed using immunofluorescence staining. Cells were fixed in 10% formalin for 30 minutes, followed by washing with a rinse buffer (2X) (20 mM Tris-Cl and 0.05% Tween-20 in PBS) (Sigma). The samples were permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 15 minutes. Cells were washed 2X with the rinse buffer, and blocked with 4% goat serum in PBS for 30 minutes. The primary antibody, osteocalcin (1:50) (R&D Systems), was added to the samples and incubated overnight at 4°C. Following the primary antibody incubation, the cells were washed 3X with the rinse buffer for 5 minutes each time. Then Alexafluor 594 (1:1000) (Invitrogen) was added to the samples and incubated for 1 hour at room temperature, followed by 4′,6-diamidino-2-phenylinde (1.25) (DAPI) (Sigma) nuclear stain. Images of stained cells were obtained using a Nikon Eclipse 80i with NIS-Elements imaging software.

To visualize the mineralized calcium, samples were fixed in 10% formalin for 30 minutes and washed 3X with DI water. Alizarin Red S staining solution (pH 4.2-4.5) (Alfa Aesar) was added to the samples and incubated for 1 hour at room temperature, followed by 4% formalin for 30 minutes. Alizarin Red S staining solution, added to the scaffold, and incubated for 30 minutes. The scaffolds were washed 3X with PBS followed by incubation in the Mayer’s Hematoxylin solution for 10 minutes. ALP was observed and imaged using a Nikon E600 light microscope.

Fabrication of PLGA resveratrol nanoparticles and determination of resveratrol release profile

Nanoparticles with diameters of 150-350 nm were synthesized through a nanoprecipitation method. Two different molecular weights of poly (lactic-co-glycolic acid) (PLGA) (Lactel Absorbable Polymers) were used to fabricate the resveratrol nanoparticles in order to test individual release profiles and optimize the resveratrol dosage in the 3D scaffolds (Table 2). A steric solution of 2.5% poly(vinyl alcohol) (Sigma) and 0.95 g of 2-morpholinoethanesulfonic acid monohydrate buffer (MES) (Sigma) pH of 5.0 in 100 mL of deionized water was created. The polymer-resveratrol encapsulation solution was made by dissolving 100 mg of PLGA and 2.5 mg of resveratrol (Sigma) in 5 mL of acetone (Macron). The polymer-resveratrol solution was added drop-wise at a rate of 1 mL/minute to the steric solution while being stirred at 300 rpm. This colloidal suspension was stirred for 24 hours to ensure complete evaporation of acetone. Nanoparticles were harvested through a centrifugation step followed by lyophilization.

Transmission Electron Microscopy (TEM) was used to analyze nanoparticle size. Briefly, nanoparticles were suspended in DI water and a drop of the solution was placed on a thin carbon film. The film was placed in a vacuum to allow for water evaporation and the sample was placed on a TEM grid. Images were taken using a JEOL 200CX transmission electron microscope.

Using a UV-Vis Spectrophotometer, a calibration curve was generated to correlate the absorption at 327 nm (peak absorbance of resveratrol) for various concentrations. Nanoparticles with different molecular weights were incubated in PBS at 37°C, and the supernatant was collected every 24 hours to read the absorbance with the UV-Vis Spectrophotometer. As it will be shown in the results, the PLGA (75:25 lactide to glycolide ratio) demonstrated the optimum release dose and was selected for use in the remainder of experiments.

Synthesis of PLGA microsphere-sintered and resveratrol nanoparticle-incorporated scaffolds

Scaffolds with diameters of 10 mm and heights of 2 mm were fabricated according to established laboratory procedures [56-58]. Briefly, PLGA (85:15 lactide to glycolide ratio) (Lactel Absorbable Polymers) was dissolved in dichloromethane (Sigma) to form a 1:4 w/v polymer solution. The solution was slowly poured into a 1% poly(vinyl alcohol) solution (Sigma) while being stirred at 330 rpm for 24 hours to allow for adequate evaporation of the solvent. Vacuum filtration was

<table>
<thead>
<tr>
<th>Lactide to Glycolide Ratio</th>
<th>Molecular Weight (kDa)</th>
<th>Functional Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>75:25</td>
<td>75-100</td>
<td>Ester Terminated</td>
</tr>
<tr>
<td>50:50</td>
<td>16-29</td>
<td>Ester Terminated</td>
</tr>
</tbody>
</table>

Table 2: The chemical characteristics of PLGA used to design nanoparticles for resveratrol encapsulation and release in scaffolds.
used to collect the microspheres, and the samples were washed with DI water and stored at -20°C for 24 hours. The microspheres were lyophilized to completely remove all moisture. Micron sieves were used to isolate microspheres of diameter 500-700 μm.

Microspheres of the size range 500-700 μm were placed into stainless steel molds, heated at 80°C for 4 hours, and sintered into cylindrical disks. Scaffolds that were to be incorporated with nanoparticles were sintered for 3.5 hours to account for the additional sintering time needed to attach nanoparticles to the microspheres.

The target resveratrol release from the nanoparticles is based on 2D studies demonstrating the optimum resveratrol dose for hMSC differentiation [53-55], and the desire to i) use acute inflammation to drive early osteogenesis and ii) switch macrophage phenotype to M2 after one week to promote wound healing and angiogenesis. To this end, initial resveratrol release was designed to attain 1-3 μM resveratrol for days 1-7, and 5-12.5 μM for days 7-21 to optimize inflammation modulation and osteogenesis of hMSCs. To accomplish this, nanoparticles were suspended in DI water at a desired concentration of 180 μg resveratrol nanoparticles/μL based on the ratio of resveratrol to PLGA in the loaded nanoparticles (1:80). Next, 10 μL of the nanoparticle solution was placed on each scaffold and allowed to disperse throughout the substrate. Scaffolds with nanoparticles were sintered for an additional 30 minutes at 85°C.


described in the section “Synthesis of PLGA microsphere-sintered nanoparticle-incorporated scaffolds.” Resveratrol nanocapsules were suspended in DI water at a desired concentration of 180 μg resveratrol nanoparticles/μL based on the ratio of resveratrol to PLGA in the loaded nanoparticles (1:80). Next, 10 μL of the nanoparticle solution was placed on each scaffold and allowed to disperse throughout the substrate. Scaffolds with nanoparticles were sintered for an additional 30 minutes at 85°C.

Novel Incorporation of Resveratrol on the Macrophage Phenotype

To confirm the effect of resveratrol on osteogenic differentiation, we analyzed the growth and lineage specification of hMSCs as cultured on resveratrol-incorporated 3D PLGA scaffolds. PLGA scaffolds were first sterilized by immersion in 70% ethanol for 10 minutes. Scaffolds were washed 3X with PBS, and exposed to UV light for 1 hour per side to further sterilize the substrates. To seed cells on scaffolds, hMSCs were trypsinized, counted, centrifuged, and resuspended in basal medium at a concentration of 2,500 cells/μL. Cell suspension was added to each scaffold at the amount of 20 μL/scaffold. Samples were incubated for 20 minutes to ensure optimum cell attachment. Next, the remaining culture medium was placed in each well containing scaffolds. Culture medium was changed to osteogenic medium after 24 hour of incubation with basal media. Cell proliferation was assessed using MTS colorimetric assay.

Osteogenic differentiation was analyzed based on the quantification of ALP and calcium expression.

Inflammatory macrophage phenotype response to resveratrol as cultured on PLGA scaffolds

THP-1 monocytes were differentiated to M1 macrophages at a seeding density of 50,000 cells/well of a 24 well plate. This was accomplished according to the protocol mentioned in the section titled “Differentiation of Monocytes to Macrophages.” Resveratrol nanoparticle-incorporated scaffolds were prepared using the method described in the section “Synthesis of PLGA microsphere-sintered and resveratrol nanoparticle-incorporated scaffolds.” Scaffolds were sterilized by immersion in 70% ethanol for 10 minutes followed by rinsing 3X with PBS. Scaffolds were placed under UV light for 1 hour per side. Scaffolds were placed in the wells with M1 macrophages and timepoints were taken at days 3, 7, 14, and 21. Gene expression of IL-6, TNF-α, IL-10, and VEGF was determined using qRT-PCR methods.

Statistical analysis

All experiments were done in triplicate. Three samples (n=3) were analyzed per condition unless otherwise stated. Studies investigating the dose dependent effect of resveratrol on M1 macrophages, the effect of resveratrol on hMSCs, and the osteogenic differentiation of hMSCs on resveratrol incorporated PLGA were done in duplicate trials. Error bars in graphs represented the mean ± standard deviation (SD). Two-way analysis of variance (two-way ANOVA) was calculated using GraphPad Prism software and used to determine statistical significance between experimental groups. One-way analysis of variance (one-way ANOVA) with a Tukey post-test was used to calculate significance between individual groups at different time points. Statistical significance was defined as p ≤ 0.05.

Results

Resveratrol modulates inflammation by inducing macrophage phenotypic switch

Figure 1 shows the dose dependent effects of resveratrol on M1 macrophages in 2D culture. Analysis of inflammatory gene (IL-6, TNF-α) and anti-inflammatory gene (VEGF, MRC-1 and IL-10) expression by qRT-PCR demonstrated that resveratrol modulates inflammation and promotes anti-inflammatory cytokine expression. Inflammation marker IL-6 was significantly lowered with the addition of 10 μM and 25 μM resveratrol at day 2, and reduced equally by all concentrations of resveratrol by day 5 (Figure 1A). Consistently, TNF-α was greatly reduced at the 2 day time point by 25 μM of resveratrol. Day 5 results showed a dose dependent trend of lowered TNF-α expression, with a statistically significant reduced inflammatory cytokine level expression in the 10 and 25 μM resveratrol containing group (Figure 1B). The expression of anti-inflammatory marker IL-10 significantly increased at day 2 and day 5 time points with the addition of 25 μM resveratrol (Figure 1C). Similarly, VEGF expression increased with the addition of resveratrol, and day 2 expression showed statistically higher levels in the 1 μM group as compared to the control (Figure 1D). By day 5, VEGF levels were the greatest with M1 macrophages cultured with 25 μM, followed by 10 μM and 1 μM. In line with these results, MRC-1 levels were significantly higher for the M1 macrophages cultured with 25 μM resveratrol at both time points, as compared to the control group (Figure 1E).

Resveratrol drives the osteogenic differentiation of hMSCs

Figure 2 demonstrates the effects of resveratrol on the osteogenic stimulation of hMSCs. Cells were cultured in either basal hMSC medium, basal medium supplemented with resveratrol, osteogenic differentiation medium, or osteogenic differentiation medium supplemented with resveratrol. Differentiation was analyzed over a period of 21 days. It is important to note that in all of our 2D studies, hMSCs exhibited a normal proliferation curve with no significant difference in cell growth between the study groups.

Osteogenesis was assessed based on calcium, ALP, and OCN expression. Calcium expression was analyzed at days 7, 14, and 21 (Figure 2A). At each time point, cells cultured in osteogenic medium supplemented with resveratrol produced significantly higher amounts
of calcium as compared to all other groups. Cells in basal medium with resveratrol as well as hMSCs cultured in osteogenic medium demonstrated a statistically higher level of calcium at days 14, and 21, as compared to the control. Calcium expression for hMSCs cultured in osteogenic medium with resveratrol is further confirmed by Alizarin Red S Staining (Figure 2B) showing a bright red color indicative of mineralized matrix.

Alkaline Phosphatase expression was determined at 7, 14, and 21 day culture time points. Cells cultured in osteogenic medium supplemented with resveratrol exhibited a statistically higher amount of ALP at every time point as compared to all. Cells cultured in osteogenic medium supplemented with resveratrol for each time point, followed by osteogenic medium at day 21. ALP staining confirmed the expression at day 21 of culture in osteogenic medium with resveratrol, as shown by the bright purple-blue color of the cells (Figure 2D).

Gene expression analysis of OCN demonstrated a significantly higher level of gene expression in the basal medium supplemented with resveratrol at day 7 (Figure 2E). At 14 and 21 day time points, cells cultured with resveratrol in osteogenic medium expressed statistically higher OCN, as compared to the control. Osteocalcin immunofluorescent staining further confirmed OCN level at day 21 expressed by hMSCs cultured in 12.5 μM resveratrol (Figure 2F).
nanoparticle-incorporated PLGA scaffolds. We observed that the cells grow in all conditions; however, hMSCs cultured on TCPS medium had significantly higher cell numbers than both the PLGA and PLGA with resveratrol groups (Figure 3A). Furthermore, the cells cultured on blank PLGA reached a significantly higher number compared to hMSCs grown on PLGA with resveratrol nanoparticles.

hMSCs cultured on resveratrol-incorporated scaffolds demonstrated significantly greater of ALP expression compared to all other experimental groups at 7, 14, and 21 day time points, while hMSCs on PLGA scaffolds produced the second highest amount of ALP at day 21 (Figure 5B). Consistently, hMSCs cultured on resveratrol nanoparticle scaffolds expressed a significantly higher amount of calcium at days 7, 14 and 21 (Figure 5C). These results were consistent with the 2D experiments demonstrating the potential of resveratrol to promote osteogenic differentiation of stem cells.

**Discussion**

Our study addresses fundamental issues facing osseointegration of biomaterial grafts in an inflammatory microenvironment. We set out to engineer an immunomodulatory and osteoinductive scaffold that can harness the osteogenic and wound healing potential of immune cells, as well as program hMSCs towards bone tissue formation. To accomplish this goal, we demonstrated the ability of resveratrol to mediate macrophage phenotype from inflammatory to wound healing as well as stimulate osteogenic differentiation of hMSCs. Building on these 2D and 3D proof-of-concept experiments, we designed a specific resveratrol nanoparticle release profile within PLGA scaffolds that would i) mediate macrophage phenotype and subsequent cytokine
These methods have faced many limitations due to immunogenicity, decomposition during the manufacturing process, and poor adhesion characteristics. Anti-inflammatory pharmaceutical drugs only temporarily suppress inflammation and have been known to reduce angiogenic factors which in turn delays wound healing. Finally, despite their important role in inflammatory cascade of events, the use of angiogenic growth factors is only partially effective due to its physiological side effects.

Instead of trying to counteract inflammation, our approach aims to utilize a natural polyphenol to regulate immune cell behavior and use their expressed signaling molecules to drive the osteogenic differentiation of hMSCs. Our methods build on the central concepts of the anti-inflammatory and osteogenic properties of resveratrol as well as the known angiogenic signaling molecules produced by macrophages. To this end, we fabricated resveratrol nanoparticle-incorporated scaffolds with a controlled release profile that have the potential to revolutionize biomaterial assimilation with native bone tissue.

Our proof of concept experiments investigating the dose dependent regulation of inflammatory cytokines by resveratrol indicated that M1 macrophages produce less IL-6 and TNF-α when cultured with the anti-inflammatory polyphenol. This is coupled with higher expression of anti-inflammatory markers VEGF, IL-10, and MRC-1 after 48 hours of exposure to resveratrol. Cells cultured with 25 μM resveratrol demonstrated the greatest expression of wound healing markers VEGF, MRC-1, and IL-10. Consistently, M1 macrophages cultured with 25 μM resveratrol exhibited the lowest amount of inflammatory cytokine TNF-α. Inflammatory marker IL-6 reduction by resveratrol was not statistically different between the 10 μM and 25 μM groups. From these results, it is clear that 25 μM resveratrol modulates inflammation to the greatest extent as compared to the other groups. However, the optimized time scale and amount of resveratrol released from the nanoparticles should account for the target temporal concentration for both osteogenesis and macrophage phenotype polarization.

The use of resveratrol as a stimulator of osteogenesis has been previously demonstrated for hMSCs, human adipose derived stem cells (hADSCs), and pre-osteoblastic MC3T3-E1 cells [55]. Furthermore, studies have shown resveratrol to affect proliferation and osteogenesis in a dose-dependent manner. hADSCs cultured with 12.5 μM, 25 μM, and 50 μM resveratrol showed the highest proliferation rate when exposed to 12.5 μM resveratrol, and the highest levels of ALP when cultured with 25 μM resveratrol. Doses of 50 μM resulted in extremely low cell numbers and ALP production. ADSCs cultured with resveratrol exhibited the highest levels of osteocalcin and osteoprotegerin at a concentration of 12.5 μM [55]. Another study concluded that doses higher than 25 μM resveratrol are potentially cytotoxic, and that 12.5 μM resveratrol exhibited the lowest amount of inflammatory cytokines TNF-α. Inflammatory marker IL-6 reduction by resveratrol was not statistically different between the 10 μM and 25 μM groups. From these results, it is clear that 25 μM resveratrol modulates inflammation to the greatest extent as compared to the other groups. However, the optimized time scale and amount of resveratrol released from the nanoparticles should account for the target temporal concentration for both osteogenesis and macrophage phenotype polarization.

The use of resveratrol as a stimulator of osteogenesis has been previously demonstrated for hMSCs, human adipose derived stem cells (hADSCs), and pre-osteoblastic MC3T3-E1 cells [55]. Furthermore, studies have shown resveratrol to affect proliferation and osteogenesis in a dose-dependent manner. hADSCs cultured with 12.5 μM, 25 μM, and 50 μM resveratrol showed the highest proliferation rate when exposed to 12.5 μM resveratrol, and the highest levels of ALP when cultured with 25 μM resveratrol. Doses of 50 μM resulted in extremely low cell numbers and ALP production. ADSCs cultured with resveratrol exhibited the highest levels of osteocalcin and osteoprotegerin at a concentration of 12.5 μM [55]. Another study concluded that doses higher than 25 μM resveratrol are potentially cytotoxic, and that 12.5 μM resveratrol exhibited the lowest amount of inflammatory cytokines TNF-α. Inflammatory marker IL-6 reduction by resveratrol was not statistically different between the 10 μM and 25 μM groups. From these results, it is clear that 25 μM resveratrol modulates inflammation to the greatest extent as compared to the other groups. However, the optimized time scale and amount of resveratrol released from the nanoparticles should account for the target temporal concentration for both osteogenesis and macrophage phenotype polarization.

Researchers have explored many options to modulate the immune response to prevent biomaterial rejection, such as using polymeric coatings, steroidal anti-inflammatory drugs, and angiogenic factors.

secretion and ii) drive the osteogenic differentiation of hMSCs. This resveratrol nanoparticle incorporated scaffold is a novel approach to enhance graft integration and assimilation with native tissue.

Researchers have explored many options to modulate the immune response to prevent biomaterial rejection, such as using polymeric coatings, steroidal anti-inflammatory drugs, and angiogenic factors.
of approximately 1.3 μM resveratrol per day for days 1-7, then approximately 5-12.5 μM resveratrol per day for days 7-21.

To design a biomaterial that allows for modulation of the immune response, one must first determine how specific aspects of inflammation such as macrophage phenotype influence wound healing and osteogenesis. Preliminary investigations on total joint replacement and the surrounding tissue histology from either i) joints that had become loose due to osteolysis, and ii) joints implanted in osteoarthritic patients, have found that the former tissue produced many M1 macrophages while the latter demonstrated M2 macrophages [64,65]. In another recent study, porosity was found to drive the higher ratio of M2/M1 macrophages when compared to the non- porous control [66]. Furthermore, scaffolds composed of natural ECM can switch macrophage phenotype to predominantly wound healing by 7-14 days after implantation [67-69]. The common thread that relates all these findings is that they all rely on altering the cytokine release profile by monocyte and macrophages to attenuate the inflammatory response to the biomaterial [70,71].

Although chronic inflammation is detrimental to wound healing and assimilation of graft with native tissue, studies have demonstrated the benefits of monocytes and macrophages in stimulating osteogenic differentiation of stem cells. In a recent published work, hMSCs were cultured in conditioned medium (CM) from M1 macrophages, M2 macrophages, and monocytes, and analyzed for hallmark osteogenic markers such as RUNX2, ALP, and bone morphogenetic protein-2 (BMP-2). hMSCs cultured with M1 CM expressed the highest levels of RUNX2, ALP, and BMP-2 [72]. Another study demonstrated that a member of the IL-6 pro-inflammatory cytokine family, Oncostatin M (OSM), produced by M1 macrophages promoted osteogenic differentiation of hMSCs and inhibited adipogenesis [73]. Macrophages secrete several osteogenic signaling molecules such as bone morphogenetic protein-2 (BMP-2), 1, 25-dihydroxyvitamin D3, interleukin-1 beta (IL-1β), and IL-6 [74-76]. During fracture healing, cytokine members of the TGF-β superfamily, such as BMP, promote different stages of wound repair. BMP-2 peaks in expression levels early in the healing process, mediates a cascade of other BMPs associated with intramembranous and endochondral ossification [77]. TNF-α is another cytokine secreted by macrophages during the initial inflammatory response that is responsible for recruiting hMSCs, and promoting cell survival [78]. Additionally, macrophages secrete angiogenic growth factors such as VEGF and PDGF, and these cytokines are important mediators in bone remodeling. Specifically, the VEGF family recruits endothelial cells, osteoblasts, and osteoclasts, and can promote microvascular endothelial cells to secrete BMPs in a hypoxic microenvironment found in fractured bone tissue [79-81].

In our proof of concept 3D experiments, we were able to successfully engineer a scaffold with a specific resveratrol release profile. M1 macrophages and hMSCs were individually placed on the scaffolds and cultured for 21 days. The gene expression profile of the macrophages showed moderately high expression of IL-6 for day 3 and day 7, and was significantly reduced by day 14. VEGF expression levels were relatively low until day 14, but significantly increased by day 21. Our method of inducing endogenous VEGF physiologic secretion from native macrophages provides a potential avenue to enhance vascular infiltration in bone scaffolds.

Stem cells cultured on the resveratrol-incorporated scaffolds expressed the highest levels of calcium and ALP, demonstrating the effectiveness of the controlled resveratrol release. The mechanism by which resveratrol induces osteogenesis is under deep investigation. Preliminary work by scientists has shown resveratrol to trigger Wnt signaling pathway leading to the upregulation of RUNX2 expression, the transcription factor essential for cell differentiation into osteoblasts [51,82]. Resveratrol also promotes osteogenesis through SIRT-1, and it has been shown that FOXO3A protein expression and SIRT-1 activation operate synergistically to mediate RUNX2 gene transcription [52,62]. When embryonic stem cell-derived mesenchymal progenitors are cultured in adipogenic medium containing resveratrol, RUNX2 and OCN are upregulated while adipogenic genes PPARY2 and LEPTIN are suppressed [62]. This is extremely important because PPARy2 can prevent RUNX2 transcription and inhibit osteogenesis [83,84]. Further studies are warranted to elucidate the temporal effect of resveratrol of osteogenic signaling pathways using appropriate in vitro and in vivo models.

This study paves the way toward harnessing the inflammatory response to biomaterials and increases the likelihood of graft integration and based on the use of a single natural dietary molecule. Further studies are to be performed to transfer the findings of this study in the clinic. One major issue to be addressed is the scale up of the resveratrol release profile in an in vivo model. In general, the rate at which drugs clear in the human body follows different kinetics as compared to controlled in vitro experiments. The morphological structure of the target tissue, density of vascular networks in the vicinity of the implant, and physiologic conditions are among many factors that affect the bioavailability and release profile. In light of the encouraging in vitro results, in vivo studies should recalibrate the release kinetics based on the pharmacological and metabolic effects of resveratrol. Another limitation of this study is apparent in its simplification of an inflammatory microenvironment surrounding a biomaterial. The complex interactions of different cell types and signaling molecules in this process is overlooked in this study to support the proof of concept. However, clinical studies should take in to account these interactions in evaluating the efficacy of this strategy in vivo. Finally, most studies to date on the hermetic behavior of resveratrol have focused on the oral consumption. Despite the positive advances, the definite test of resveratrol’s pharmacokinetics and toxic effects, as released directly in the tissue, will elucidate the mechanisms of action and potential use in tissue engineering and regenerative medicine.

Acknowledgement

We gratefully acknowledge support from the National Institutes of Health grants (NIH P20 GM103641), and (NIH AR063338), and National Science Foundation grant (EPS-0903795).

References


